阿尔茨海默病和 帕金森病 ...

Canada: Recent post hoc analyses from the VERTIS CV trial reveal promising results for ertugliflozin, a medication used to ...

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

该研究揭示了SGLT2抑制剂靶向CD8+ T细胞内的酮体代谢以改善MASH的病理生理学机制，为将来SGLT2抑制剂作为“老药新用”的治疗策略提供了一个重要的科学依据。 南方医科大学南方医院张惠杰教授团队联合广东省人民医院杨魏教授及山西医科大学附属第二医院李晋 ...

在研究人员调整了其他可能影响痴呆或帕金森病风险的因素，如糖尿病和药物并发症后，他们发现使用SGLT2抑制剂与阿尔茨海默病风险降低20%和帕金森病风险降低20%相关。服用这些药物的人患血管性痴呆的风险降低了30%。

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

专利悬崖期即将到来，销售还在快速放量，单药全球销量在专利到期后预计可达百亿美元，谁能分拆“重磅炸弹”原研市场？ 中印药企在国内，开启60亿大单品抢仿之争Guide View ...